Avanos Medical, Inc.
NYSE:AVNSMedical - Devices
+$0.06 today
- Market cap
- $1.17B
- Beta
- 1.57
- P/E (TTM)
- -16.7
- EPS (TTM)
- -$1.50
Volume 0.43M
Average 1.49M
AVNS Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Avanos Medical, Inc.NYSE: AVNS
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue growth accelerates
Q1 FY2026 revenue of $182.2M rose 8.8% year over year, ahead of the +3.9% change in trailing-twelve-month revenue. Sequentially, it rose 0.7% from the prior quarter. Over 3 fiscal years it compounded at +0.8% a year.
Context
- Revenue increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 1 analysts of $710M (+1.3%) for the fiscal year ending Dec 2026, a pace similar to FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $182.2M+0.7% QoQ
- Last fiscal yearDec 2025
- $701.2M+1.9% YoY
- LTMMar 2026
- $715.9M+3.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +8.8% | -1.1% | -9.9 pp |
| 1 year | +1.9% | +1.3% | -0.7 pp |
| 3-year CAGR | +0.8% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 701.2M USD
- Year-over-year change
- +1.9%
- 4-year CAGR
- -1.5%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 701.2M | +1.9% |
| FY2024 | 2024-12-31 | 687.8M | +2.2% |
| FY2023 | 2023-12-31 | 673.3M | -1.6% |
| FY2022 | 2022-12-31 | 684.1M | -8.1% |
| FY2021 | 2021-12-31 | 744.6M | — |
Revenue vs competitors
How AVNS compares with its peers on the latest reported figures
- AVNS's LTM Mar 2026 revenue of $715.9M is the 3rd highest of the 11 companies compared; the peer median is $127.55M.
- Its year-over-year change of +3.9% is the 7th highest of 11, against a peer median of +15.5%.
- Over three fiscal years its annual growth of +0.8% compares with a peer median of +7.4%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $21.48B | +69.8% | +0.7% | |
| LTM Apr 2026 | $857.5M | +3.6% | -0.6% | |
| LTM Mar 2026 | $715.9M | +3.9% | +0.8% | |
| LTM Mar 2026 | $576.3M | +1.5% | +3.5% | |
| LTM Mar 2026 | $204.17M | +3.6% | +7.1% | |
| LTM Mar 2026 | $160.03M | +5.0% | +7.6% | |
CBLLCeriBell, Inc. | LTM Mar 2026 | $95.07M | +33.7% | +50.9% |
| LTM Mar 2026 | $88.24M | +383560.9% | +200.9% | |
| LTM Mar 2026 | $86.26M | -35.8% | -4.5% | |
| LTM Mar 2026 | $63.5M | +146.9% | +71.2% | |
| LTM Mar 2026 | $40.61M | +26.0% | +21.6% | |
| Peer median (excluding AVNS) | $127.55M | +15.5% | +7.4% | |
Competitors are the stored peer set for AVNS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 744.6M | 684.1M | 673.3M | 687.8M | 701.2M |
| Cost of Revenue | 364.7M | 289.9M | 293.6M | 306.5M | 352.2M |
| Gross Profit | 379.9M | 394.2M | 379.7M | 381.3M | 349M |
| Gross Margin | 51.0% | 57.6% | 56.4% | 55.4% | 49.8% |
| Research & Development | 32.3M | 30.6M | 27.2M | 26.2M | 23.1M |
| Selling, General & Admin | 260.8M | 323.1M | 287.5M | 315.1M | 218.3M |
| Operating Expenses | 293.1M | 352.3M | 314.7M | 341.3M | 410.6M |
| Depreciation & Amortization | 38.3M | 41.1M | 43.5M | 45.5M | 29M |
| EBITDA | 48.9M | 77.8M | 50.6M | (345.6M) | (33.2M) |
| EBITDA Margin | 6.6% | 11.4% | 7.5% | -50.2% | -4.7% |
| Operating Income | 86.8M | 41.9M | 65M | 40M | (61.6M) |
| Operating Margin | 11.7% | 6.1% | 9.7% | 5.8% | -8.8% |
| Interest Income | 200K | 1.2M | 2.9M | 5.1M | 3.2M |
| Interest Expense | 3.3M | 10M | 15M | 12.2M | 4M |
| Other Income / Expenses | (79.5M) | (15.2M) | (72.9M) | (443.3M) | (4.6M) |
| Income Before Tax | 7.3M | 26.7M | (7.9M) | (403.3M) | (66.2M) |
| Pre-Tax Margin | 1.0% | 3.9% | -1.2% | -58.6% | -9.4% |
| Income Tax Expense | 1M | 5.2M | 2M | (17M) | 1.7M |
| Net Income | 6.3M | 50.5M | (61.8M) | (392.1M) | (67.9M) |
| Net Margin | 0.8% | 7.4% | -9.2% | -57.0% | -9.7% |
| EPS (Basic) | 0.13 | 1.08 | (1.33) | (8.53) | (1.46) |
| EPS (Diluted) | 0.13 | 1.07 | (1.33) | (8.53) | (1.46) |
| Weighted Avg Shares | 48.1M | 46.9M | 46.6M | 46M | 46.4M |
| Weighted Avg Shares (Diluted) | 48.6M | 47.3M | 46.6M | 46M | 46.4M |
Avanos Medical, Inc.
NYSE:AVNS
Intrinsic Alpha fair value
Locked
Current Price
$24.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.